Search

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner

Indigenous communities and partners unite to bridge gaps in healthcare through PATHWAYS initiative

New health projects empower Indigenous communities to address chronic diseases

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.

Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Protect your dog from parasites, inside and out

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada

World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

Virtual care pharmacy services offered in Alberta long-term care facilities

Ontario’s Dr. Trevor DeVries named 2021 Metacam® 20 Bovine Welfare Award winner

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner

Indigenous communities and partners unite to bridge gaps in healthcare through PATHWAYS initiative

New health projects empower Indigenous communities to address chronic diseases

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Protect your dog from parasites, inside and out

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada

World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

Virtual care pharmacy services offered in Alberta long-term care facilities

Ontario’s Dr. Trevor DeVries named 2021 Metacam® 20 Bovine Welfare Award winner

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 